CBD shows promise against oral bacteria in early lab research
Cannabidiol (CBD) Inhibits Streptococcus oralis Growth and Biofilm Formation, While Maintaining Human Gingival Epithelial Cell Viability: An In Vitro Study.
AI Summary
This in vitro study found that cannabidiol (CBD) inhibited the growth of Streptococcus oralis, a bacterium involved in oral biofilm formation. The effect increased with CBD concentration: the reported minimum inhibitory concentration was 6.25 μg/mL, while the minimum bactericidal concentration was 25 μg/mL. CBD also disrupted the structure of S. oralis biofilms, with effects observed even at 3.12 μg/mL.
At the CBD concentrations tested—3.12, 6.25, and 12.5 μg/mL—human gingival epithelial cells maintained their viability after 24 hours of exposure. These results provide preliminary evidence that CBD may have antimicrobial and antibiofilm potential in oral-health applications. However, the research was conducted in laboratory cultures, not in people, so it does not show that CBD products prevent gum disease, treat oral infections, or are safe and effective for use in the mouth.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
Cancer lab findings have not established cannabinoids as disease-modifying…
In mice, THC lowered observed seizure severity but caused marked sedation
Review surveys nanocrystals for phytochemicals, including CBD, and their…
Explore More Research
Stay informed about the latest cannabis science.